RUO block, masked “RP-300”, a COA, ≥99% specs, an LC-MS identity line — it reads like the compliant product page. Here's what an acquirer, the FTC, or Lilly/Novo would actually find.
- 1
IN THE <TITLE> & METAPage heading is a clean “RP-300”.The browser-tab title is “Buy Retatrutide (GLP-3) Research Peptide… RP-300” — scraped first.
- 3
“FDA-Registered Facility · cGMP” reads as quality.Registration ≠ approval/endorsement (prohibited); cGMP unsubstantiated.
- 4
IN THE IMAGE ALT TEXTVial reads “RP-300”.Alt text: “retatrutide glp-3 semaglutide research peptide vial”.
- 5
“4.9 ★ · 412 research reviews”.Star reviews = consumer signal + FTC fake-review exposure.
- 6
“Visa/Mastercard accepted” seems normal.The masked GLP class must stay OFF the scraped card rail.
- 7
A neutral code, RP-300.“Triple agonist of GLP-1, GIP & glucagon… weight-management research” names the class, mechanism & human-use signal in one line.
- 8
“Format” looks like a spec.“Injection-ready, USP grade” is a human dosage form = intended-use evidence (21 CFR 201.128).
- 9
IN THE COA FILENAMEA COA is linked (good).The file is “retatrutide-glp3-coa.pdf” — and the PDF states it. The masking is undone on discovery; the GLP COA should be gated by request.
- 10
“Frequently purchased together” is e-commerce.RP-300 + AOD-9604 + 5-Amino-1MQ = a recognized fat-loss stack = protocol recommendation.
- 12
“Storage & reconstitution” sounds like handling.“Reconstitute, refrigerate, use within 8 weeks” = human-use prep & use.
- 13
INSIDE THE TERMSA Terms link is present.It's an unedited template (wrong platform, blank governing law) — unenforceable.
